<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="protocol"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="hwp">bmjopen</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23535703</article-id><article-id pub-id-type="pmc">3612795</article-id><article-id pub-id-type="publisher-id">bmjopen-2013-002759</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2013-002759</article-id><article-categories><subj-group subj-group-type="heading"><subject>Infectious Diseases</subject><subj-group><subject>Protocol</subject></subj-group></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject><subject>1706</subject><subject>1692</subject><subject>1694</subject><subject>1699</subject><subject>1723</subject><subject>1730</subject></subj-group></article-categories><title-group><article-title>Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda</article-title><alt-title alt-title-type="short">Dose-finding trial for single-dose primaquine to block malaria transmission</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Eziefula</surname><given-names>Alice Chijioke</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Staedke</surname><given-names>Sarah G</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yeung</surname><given-names>Shunmay</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Webb</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kamya</surname><given-names>Moses</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Nicholas J</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bousema</surname><given-names>Teun</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Drakeley</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Faculty of Infectious and Tropical Diseases</addr-line>, <institution>London School of Hygiene and Tropical Medicine</institution>, <addr-line>London</addr-line>, <country>UK</country></aff><aff id="af2"><label>2</label><addr-line>Faculty of Epidemiology and Population Health</addr-line>, <institution>London School of Hygiene and Tropical Medicine</institution>, <addr-line>London</addr-line>, <country>UK</country></aff><aff id="af3"><label>3</label><institution>Infectious Diseases Research Collaboration</institution>, <addr-line>Kampala</addr-line>, <country>Uganda</country></aff><aff id="af4"><label>4</label><addr-line>Mahidol Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine</addr-line>, <institution>Mahidol University</institution>, <addr-line>Bangkok</addr-line>, <country>Thailand</country></aff><aff id="af5"><label>5</label><addr-line>Department of Medical Microbiology</addr-line>, <institution>Radboud University Nijmegen Medical Centre</institution>, <addr-line>Nijmegen</addr-line>, <country>The Netherlands</country></aff><author-notes><corresp><label>Correspondence to</label> Dr Alice C Eziefula; <email>chi.eziefula@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>26</day><month>3</month><year>2013</year></pub-date><volume>3</volume><issue>3</issue><elocation-id>e002759</elocation-id><history><date date-type="received"><day>19</day><month>2</month><year>2013</year></date><date date-type="accepted"><day>25</day><month>2</month><year>2013</year></date></history><permissions><copyright-statement>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access"><license-p>this is an open-access article distributed under the terms of the creative commons attribution non-commercial license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. see: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/">http://creativecommons.org/licenses/by-nc/2.0/</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/legalcode">http://creativecommons.org/licenses/by-nc/2.0/legalcode</ext-link>.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="bmjopen-2013-002759.pdf"></self-uri><self-uri content-type="draft-revisions-pdf" xlink:type="simple" xlink:href="bmjopen-2013-002759.draft_revisions.pdf"></self-uri><abstract><sec><title><offsets xml_i="5877" xml_f="5887" txt_i="11" txt_f="21">Objectives</offsets></title><p><offsets xml_i="5898" xml_f="5942" txt_i="22" txt_f="66">For the purpose of blocking transmission of </offsets><italic><offsets xml_i="5950" xml_f="5971" txt_i="66" txt_f="87">Plasmodium falciparum</offsets></italic><offsets xml_i="5980" xml_f="6588" txt_i="87" txt_f="695"> malaria from humans to mosquitoes, a single dose of primaquine is recommended by the WHO as an addition to artemisinin combination therapy. Primaquine clears gametocytes but causes dose-dependent haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Evidence is needed to inform the optimal dosing of primaquine for malaria elimination programmes and for the purpose of interrupting the spread of artemisinin-resistant malaria. This study investigates the efficacy and safety of reducing doses of primaquine for clearance of gametocytes in participants with normal G6PD status.</offsets></p></sec><sec><title><offsets xml_i="6610" xml_f="6630" txt_i="697" txt_f="717">Methods and analysis</offsets></title><p><offsets xml_i="6641" xml_f="6815" txt_i="718" txt_f="892">In this prospective, four-armed randomised placebo-controlled double-blinded trial, children aged 1–10 years, weighing over 10 kg, with haemoglobin ≥8 g/dl and uncomplicated </offsets><italic><offsets xml_i="6823" xml_f="6835" txt_i="892" txt_f="904">P falciparum</offsets></italic><offsets xml_i="6844" xml_f="7852" txt_i="904" txt_f="1912"> malaria are treated with artemether lumefantrine and randomised to receive a dose of primaquine (0.1, 0.4 or 0.75 mg base/kg) or placebo on the third day of treatment. Participants are followed up for 28 days. Gametocytaemia is measured by quantitative nucleic acid sequence-based analysis on days 0, 2, 3, 7, 10 and 14 with a primary endpoint of the number of days to gametocyte clearance in each treatment arm and secondarily the area under the curve of gametocyte density over time. Analysis is for non-inferiority of efficacy compared to the reference dose, 0.75 mg base/kg. Safety is assessed by pair-wise comparisons of the arithmetic mean (±SD) change in haemoglobin concentration per treatment arm and analysed for superiority to placebo and incidence of adverse events. Ethics and dissemination Approval was obtained from the ethical committees of Makerere University School of Medicine, the Ugandan National Council of Science and Technology and the London School of Hygiene and Tropical Medicine.</offsets></p></sec><sec><title><offsets xml_i="7874" xml_f="7881" txt_i="1914" txt_f="1921">Results</offsets></title><p><offsets xml_i="7892" xml_f="8018" txt_i="1922" txt_f="2048">These will be disseminated to inform malaria elimination policy, through peer-reviewed publication and academic presentations.</offsets></p></sec></abstract><kwd-group><kwd>Infectious diseases</kwd><kwd>Parasitology</kwd><kwd>Public health</kwd></kwd-group></article-meta></front><body><boxed-text position="float"><caption><title><offsets xml_i="8213" xml_f="8228" txt_i="2057" txt_f="2072">Article summary</offsets></title></caption><sec><title><offsets xml_i="8258" xml_f="8271" txt_i="2073" txt_f="2086">Article focus</offsets></title><list list-type="bullet"><list-item><p><offsets xml_i="8318" xml_f="8425" txt_i="2087" txt_f="2194">Single-dose primaquine, administered together with artemisinin combination therapy, blocks transmission of </offsets><italic><offsets xml_i="8433" xml_f="8454" txt_i="2194" txt_f="2215">Plasmodium falciparum</offsets></italic><offsets xml_i="8463" xml_f="8496" txt_i="2215" txt_f="2248"> malaria by clearing gametocytes.</offsets></p></list-item><list-item><p><offsets xml_i="8526" xml_f="8741" txt_i="2249" txt_f="2464">Primaquine, an 8-aminoquinoline, causes dose-dependent haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Evidence is lacking on the safety and efficacy of lower doses of primaquine.</offsets></p></list-item><list-item><p><offsets xml_i="8771" xml_f="8850" txt_i="2465" txt_f="2544">This is the protocol of a dose-finding trial being conducted in eastern Uganda.</offsets></p></list-item></list></sec><sec><title><offsets xml_i="8891" xml_f="8903" txt_i="2546" txt_f="2558">Key messages</offsets></title><list list-type="bullet"><list-item><p><offsets xml_i="8950" xml_f="9094" txt_i="2559" txt_f="2703">Dose-finding is a priority for the use of primaquine in malaria elimination programmes and to block the spread of artemisinin-resistant malaria.</offsets></p></list-item><list-item><p><offsets xml_i="9124" xml_f="9245" txt_i="2704" txt_f="2825">This trial is designed to investigate the efficacy and safety of reducing doses of primaquine for gametocytocidal action.</offsets></p></list-item><list-item><p><offsets xml_i="9275" xml_f="9503" txt_i="2826" txt_f="3054">This paper highlights the unique trial design issues that are relevant for investigating the efficacy and safety of antimalarials targeted against the sexual stages of malaria for blocking transmission rather than clinical cure.</offsets></p></list-item></list></sec><sec><title><offsets xml_i="9544" xml_f="9583" txt_i="3056" txt_f="3095">Strengths and limitations of this study</offsets></title><list list-type="bullet"><list-item><p><offsets xml_i="9630" xml_f="9828" txt_i="3096" txt_f="3294">For ethical reasons, in this trial, dose-finding is conducted in children with normal G6PD status, but, ultimately, information is needed on the safety of lower doses in people with G6PD deficiency.</offsets></p></list-item><list-item><p><offsets xml_i="9858" xml_f="10082" txt_i="3295" txt_f="3519">This trial measures primaquine's transmission-blocking potential by assessing gametocyte clearance. Endpoints of mosquito transmission at multiple time points could be usefully assessed but on smaller numbers of individuals.</offsets></p></list-item></list></sec></boxed-text><sec id="s1"><title><offsets xml_i="10144" xml_f="10154" txt_i="3521" txt_f="3531">Background</offsets></title><p><offsets xml_i="10165" xml_f="10284" txt_i="3532" txt_f="3651">Sustained deployment of vector control measures and accessible, effective drug therapy has reduced the transmission of </offsets><italic><offsets xml_i="10292" xml_f="10313" txt_i="3651" txt_f="3672">Plasmodium falciparum</offsets></italic><offsets xml_i="10322" xml_f="10486" txt_i="3672" txt_f="3836"> in many endemic countries. However, further scaling-up of currently available malaria control measures is unlikely to achieve malaria elimination in most settings.</offsets><xref ref-type="bibr" rid="R1"><offsets xml_i="10517" xml_f="10518" txt_i="3836" txt_f="3837">1</offsets></xref><offsets xml_i="10525" xml_f="10597" txt_i="3837" txt_f="3909"> Moreover, the emergence of resistance to artemisinin in Southeast Asia,</offsets><xref ref-type="bibr" rid="R2"><offsets xml_i="10628" xml_f="10629" txt_i="3909" txt_f="3910">2</offsets></xref><offsets xml_i="10636" xml_f="10637" txt_i="3910" txt_f="3911">
</offsets><xref ref-type="bibr" rid="R3"><offsets xml_i="10668" xml_f="10669" txt_i="3911" txt_f="3912">3</offsets></xref><offsets xml_i="10676" xml_f="10768" txt_i="3912" txt_f="4004"> and the development of insecticide resistance and adaptive behaviour in the mosquito vector</offsets><xref ref-type="bibr" rid="R4"><offsets xml_i="10799" xml_f="10801" txt_i="4004" txt_f="4006">4–</offsets></xref><offsets xml_i="10808" xml_f="10809" txt_i="4006" txt_f="4007">–</offsets><xref ref-type="bibr" rid="R6"><offsets xml_i="10840" xml_f="10841" txt_i="4007" txt_f="4008">6</offsets></xref><offsets xml_i="10848" xml_f="11118" txt_i="4008" txt_f="4278"> present significant threats to the current trend of declining malaria burden. Malaria elimination initiatives and artemisinin-resistance containment strategies both require additional tools that are specifically aimed at reducing the transmission of malarial parasites.</offsets><xref ref-type="bibr" rid="R7"><offsets xml_i="11149" xml_f="11150" txt_i="4278" txt_f="4279">7</offsets></xref><offsets xml_i="11157" xml_f="11158" txt_i="4279" txt_f="4280">
</offsets><xref ref-type="bibr" rid="R8"><offsets xml_i="11189" xml_f="11190" txt_i="4280" txt_f="4281">8</offsets></xref></p><p><offsets xml_i="11204" xml_f="11441" txt_i="4282" txt_f="4519">Antimalarial drugs are designed primarily to target the asexual stages of the parasite that cause morbidity and mortality. The effect of antimalarial drugs on gametocytes, the transmission stages, has for decades been seen as ancillary. </offsets><italic><offsets xml_i="11449" xml_f="11461" txt_i="4519" txt_f="4531">P falciparum</offsets></italic><offsets xml_i="11470" xml_f="11587" txt_i="4531" txt_f="4648"> gametocytes undergo complex development that is characterised by five morphologically distinct stages of maturation.</offsets><xref ref-type="bibr" rid="R9"><offsets xml_i="11618" xml_f="11619" txt_i="4648" txt_f="4649">9</offsets></xref><offsets xml_i="11626" xml_f="11731" txt_i="4649" txt_f="4754"> The immature gametocyte stages (I–IV) are sequestered in the reticuloendothelial system and bone marrow.</offsets><xref ref-type="bibr" rid="R10"><offsets xml_i="11763" xml_f="11766" txt_i="4754" txt_f="4757">10–</offsets></xref><offsets xml_i="11773" xml_f="11774" txt_i="4757" txt_f="4758">–</offsets><xref ref-type="bibr" rid="R12"><offsets xml_i="11806" xml_f="11808" txt_i="4758" txt_f="4760">12</offsets></xref><offsets xml_i="11815" xml_f="12047" txt_i="4760" txt_f="4992"> Mature stage V gametocytes typically appear approximately 12 days after the onset of patent asexual bloodstream infection, and are the only gametocyte stage that circulates in the peripheral blood and is infective to biting female </offsets><italic><offsets xml_i="12055" xml_f="12064" txt_i="4992" txt_f="5001">Anopheles</offsets></italic><offsets xml_i="12073" xml_f="12085" txt_i="5001" txt_f="5013"> mosquitoes.</offsets><xref ref-type="bibr" rid="R13"><offsets xml_i="12117" xml_f="12119" txt_i="5013" txt_f="5015">13</offsets></xref><offsets xml_i="12126" xml_f="12127" txt_i="5015" txt_f="5016">
</offsets><xref ref-type="bibr" rid="R14"><offsets xml_i="12159" xml_f="12161" txt_i="5016" txt_f="5018">14</offsets></xref><offsets xml_i="12168" xml_f="12307" txt_i="5018" txt_f="5157"> The majority of antimalarial drugs, including artemisinins, lumefantrine and piperaquine, have some efficacy against immature gametocytes.</offsets><xref ref-type="bibr" rid="R15"><offsets xml_i="12339" xml_f="12341" txt_i="5157" txt_f="5159">15</offsets></xref><offsets xml_i="12348" xml_f="12349" txt_i="5159" txt_f="5160">
</offsets><xref ref-type="bibr" rid="R16"><offsets xml_i="12381" xml_f="12383" txt_i="5160" txt_f="5162">16</offsets></xref><offsets xml_i="12390" xml_f="12785" txt_i="5162" txt_f="5557"> These drugs have the potential to reduce transmission at a population level because asexual parasites are cleared, preventing de novo development of gametocytes, and fewer of the immature gametocytes that are present upon initiation of treatment survive to maturity. However, the vast majority of symptomatic cases have measurable and transmissible levels of mature gametocytes at presentation.</offsets><xref ref-type="bibr" rid="R17"><offsets xml_i="12817" xml_f="12819" txt_i="5557" txt_f="5559">17</offsets></xref><offsets xml_i="12826" xml_f="12827" txt_i="5559" txt_f="5560">
</offsets><xref ref-type="bibr" rid="R18"><offsets xml_i="12859" xml_f="12861" txt_i="5560" txt_f="5562">18</offsets></xref><offsets xml_i="12868" xml_f="13120" txt_i="5562" txt_f="5814"> These persist after treatment with all antimalarials that are currently implemented as first-line treatment, including artemisinin combination therapy (ACT). Gametocytes that persist after ACT have repeatedly been shown to be infectious to mosquitoes.</offsets><xref ref-type="bibr" rid="R17"><offsets xml_i="13152" xml_f="13154" txt_i="5814" txt_f="5816">17</offsets></xref><offsets xml_i="13161" xml_f="13162" txt_i="5816" txt_f="5817">
</offsets><xref ref-type="bibr" rid="R19"><offsets xml_i="13194" xml_f="13196" txt_i="5817" txt_f="5819">19</offsets></xref><offsets xml_i="13203" xml_f="13204" txt_i="5819" txt_f="5820">
</offsets><xref ref-type="bibr" rid="R20"><offsets xml_i="13236" xml_f="13238" txt_i="5820" txt_f="5822">20</offsets></xref><offsets xml_i="13245" xml_f="13377" txt_i="5822" txt_f="5954"> This post-treatment gametocyte carriage frequently occurs at low densities, commonly below the microscopic threshold for detection,</offsets><xref ref-type="bibr" rid="R21"><offsets xml_i="13409" xml_f="13411" txt_i="5954" txt_f="5956">21</offsets></xref><offsets xml_i="13418" xml_f="13419" txt_i="5956" txt_f="5957">
</offsets><xref ref-type="bibr" rid="R22"><offsets xml_i="13451" xml_f="13453" txt_i="5957" txt_f="5959">22</offsets></xref><offsets xml_i="13460" xml_f="13519" txt_i="5959" txt_f="6018"> but is sufficiently high for efficient mosquito infection.</offsets><xref ref-type="bibr" rid="R17"><offsets xml_i="13551" xml_f="13553" txt_i="6018" txt_f="6020">17</offsets></xref><offsets xml_i="13560" xml_f="13561" txt_i="6020" txt_f="6021">
</offsets><xref ref-type="bibr" rid="R23"><offsets xml_i="13593" xml_f="13595" txt_i="6021" txt_f="6023">23</offsets></xref></p><p><offsets xml_i="13609" xml_f="13667" txt_i="6024" txt_f="6082">The only class of drugs that are effective against mature </offsets><italic><offsets xml_i="13675" xml_f="13687" txt_i="6082" txt_f="6094">P falciparum</offsets></italic><offsets xml_i="13696" xml_f="13970" txt_i="6094" txt_f="6368"> gametocytes is the 8-aminoquinolines. Primaquine is the most widely available drug in this class. The exact mechanism for this gametocytocidal activity is unknown, but it is probably dependent on oxidative damage to the intraerythrocytic parasite by primaquine metabolites.</offsets><xref ref-type="bibr" rid="R24"><offsets xml_i="14002" xml_f="14004" txt_i="6368" txt_f="6370">24</offsets></xref><offsets xml_i="14011" xml_f="14132" txt_i="6370" txt_f="6491"> Primaquine as a single dose of 0.75 mg base/kg added to standard ACT has superior gametocytocidal activity to ACT alone.</offsets><xref ref-type="bibr" rid="R25"><offsets xml_i="14164" xml_f="14167" txt_i="6491" txt_f="6494">25–</offsets></xref><offsets xml_i="14174" xml_f="14175" txt_i="6494" txt_f="6495">–</offsets><xref ref-type="bibr" rid="R27"><offsets xml_i="14207" xml_f="14209" txt_i="6495" txt_f="6497">27</offsets></xref><offsets xml_i="14216" xml_f="14640" txt_i="6497" txt_f="6921"> All doses of primaquine described hereafter refer to the dose of primaquine base per unit weight. There are indications that doses of primaquine lower than 0.75 mg/kg may be equally efficacious. A Thai study showed that both 0.5 and 0.25 mg/kg of primaquine administered with ACT to adults infected with malaria effectively and indistinguishably reduced the proportion of mosquitoes that became infected after a blood meal.</offsets><xref ref-type="bibr" rid="R28"><offsets xml_i="14672" xml_f="14674" txt_i="6921" txt_f="6923">28</offsets></xref><offsets xml_i="14681" xml_f="14825" txt_i="6923" txt_f="7067"> In small numbers of adults, total doses of 30 mg and 15 mg have shown comparable efficacy to a 45 mg dose in reducing mosquito infection rates.</offsets><xref ref-type="bibr" rid="R29"><offsets xml_i="14857" xml_f="14859" txt_i="7067" txt_f="7069">29</offsets></xref><offsets xml_i="14866" xml_f="14867" txt_i="7069" txt_f="7070">
</offsets><xref ref-type="bibr" rid="R30"><offsets xml_i="14899" xml_f="14901" txt_i="7070" txt_f="7072">30</offsets></xref></p><p><offsets xml_i="14915" xml_f="15187" txt_i="7073" txt_f="7345">The efficacy of primaquine when given as a single low dose is important in the light of concerns over the haematological safety of primaquine. There is conclusive evidence for primaquine-induced haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals.</offsets><xref ref-type="bibr" rid="R31"><offsets xml_i="15219" xml_f="15221" txt_i="7345" txt_f="7347">31</offsets></xref><offsets xml_i="15228" xml_f="15229" txt_i="7347" txt_f="7348">
</offsets><xref ref-type="bibr" rid="R32"><offsets xml_i="15261" xml_f="15263" txt_i="7348" txt_f="7350">32</offsets></xref><offsets xml_i="15270" xml_f="15714" txt_i="7350" txt_f="7794"> G6PD deficient individuals are vulnerable to oxidative stress because their erythrocytes do not have alternative pathways for G6PD-dependent nicotinamide adenine dinucleotide phosphate production, which is essential to maintain antioxidant defences. There is conflicting evidence on the risk of haemolysis after a single dose of primaquine. A single dose of 45 mg primaquine administered to a Vanuatan adult caused life-threatening haemolysis.</offsets><xref ref-type="bibr" rid="R33"><offsets xml_i="15746" xml_f="15748" txt_i="7794" txt_f="7796">33</offsets></xref><offsets xml_i="15755" xml_f="15993" txt_i="7796" txt_f="8034"> In G6PD-deficient Tanzanian children, the mean fall in haemoglobin after a single dose of 0.75 mg/kg primaquine was 2.5 g/dl (95% CI 1.2 to 3.8 g/dl), though no associated severe adverse events were recorded and haemolysis was transient.</offsets><xref ref-type="bibr" rid="R34"><offsets xml_i="16025" xml_f="16027" txt_i="8034" txt_f="8036">34</offsets></xref><offsets xml_i="16034" xml_f="16215" txt_i="8036" txt_f="8217"> On the other hand, primaquine was reported to be well tolerated when 0.75 mg/kg was given without prior G6PD testing in large studies in Myanmar, Sudan, Russia, Cambodia and China.</offsets><xref ref-type="bibr" rid="R27"><offsets xml_i="16247" xml_f="16249" txt_i="8217" txt_f="8219">27</offsets></xref><offsets xml_i="16256" xml_f="16257" txt_i="8219" txt_f="8220">
</offsets><xref ref-type="bibr" rid="R31"><offsets xml_i="16289" xml_f="16291" txt_i="8220" txt_f="8222">31</offsets></xref><offsets xml_i="16298" xml_f="16299" txt_i="8222" txt_f="8223">
</offsets><xref ref-type="bibr" rid="R35"><offsets xml_i="16331" xml_f="16333" txt_i="8223" txt_f="8225">35</offsets></xref><offsets xml_i="16340" xml_f="16341" txt_i="8225" txt_f="8226">
</offsets><xref ref-type="bibr" rid="R36"><offsets xml_i="16373" xml_f="16375" txt_i="8226" txt_f="8228">36</offsets></xref></p><p><offsets xml_i="16389" xml_f="16445" txt_i="8229" txt_f="8285">Because primaquine-induced haemolysis is dose-dependent,</offsets><xref ref-type="bibr" rid="R29"><offsets xml_i="16477" xml_f="16479" txt_i="8285" txt_f="8287">29</offsets></xref><offsets xml_i="16486" xml_f="16890" txt_i="8287" txt_f="8691"> and because gametocytocidal efficacy may be retained with primaquine doses lower than 0.75 mg/kg, the WHO-recommended dose in its 2010 Guidelines for the Treatment of Malaria, dose-finding studies are needed urgently. This trial tests the hypothesis that lower doses of primaquine have a substantially lower risk of, or an absence of, adverse effects but that their gametocytocidal efficacy is retained.</offsets></p></sec><sec id="s2"><title><offsets xml_i="16920" xml_f="16940" txt_i="8693" txt_f="8713">Methods and analysis</offsets></title><sec id="s2a"><title><offsets xml_i="16969" xml_f="16981" txt_i="8714" txt_f="8726">Study design</offsets></title><p><offsets xml_i="16992" xml_f="17219" txt_i="8727" txt_f="8954">The study is a prospective, randomised, parallel arm, placebo-controlled, double-blinded clinical trial of reducing doses of primaquine administered with artemether lumefantrine (AL) for the treatment of uncomplicated clinical </offsets><italic><offsets xml_i="17227" xml_f="17239" txt_i="8954" txt_f="8966">P falciparum</offsets></italic><offsets xml_i="17248" xml_f="17490" txt_i="8966" txt_f="9208"> malaria infection in children aged 1–10 years of age. The study uses a non-inferiority design to evaluate the efficacy and a superiority design to evaluate the safety of 0.1 and 0.4 mg/kg primaquine compared with 0.75 mg/kg when added to AL.</offsets></p></sec><sec id="s2b"><title><offsets xml_i="17521" xml_f="17537" txt_i="9210" txt_f="9226">Study objectives</offsets></title><list list-type="order"><list-item><p><offsets xml_i="17583" xml_f="17748" txt_i="9227" txt_f="9392">To evaluate the efficacy of 0.1, 0.4 and 0.75 mg/kg primaquine when administered together with the fifth dose of AL as measured by gametocyte prevalence and density.</offsets></p></list-item><list-item><p><offsets xml_i="17778" xml_f="18035" txt_i="9393" txt_f="9647">To evaluate the safety of 0.1, 0.4 and 0.75 mg/kg primaquine when administered together with the fifth dose of AL as measured by change in mean haemoglobin, prevalence of severe anaemia (haemoglobin &lt;5 g/dl) and evidence of black urine (haemoglobinuria).</offsets></p></list-item><list-item><p><offsets xml_i="18065" xml_f="18267" txt_i="9648" txt_f="9850">To assess the safety of different doses of 0.1, 0.4 and 0.75 mg/kg primaquine when administered together with the fifth dose of AL as measured by prevalence/incidence of adverse events and tolerability.</offsets></p></list-item></list></sec><sec id="s2c"><title><offsets xml_i="18317" xml_f="18343" txt_i="9852" txt_f="9878">Participants and enrolment</offsets></title><p><offsets xml_i="18354" xml_f="18647" txt_i="9879" txt_f="10172">The study is conducted at Walukuba Health Centre IV in Walukuba subcounty, Jinja district, in eastern Uganda. In this area, malaria transmission is year-round with two seasonal peaks. The entomological inoculation rate (EIR) was estimated at 7 infectious bites per person per year in Walukuba.</offsets><xref ref-type="bibr" rid="R37"><offsets xml_i="18679" xml_f="18681" txt_i="10172" txt_f="10174">37</offsets></xref><offsets xml_i="18688" xml_f="18791" txt_i="10174" txt_f="10277"> Study participants are recruited from children attending the Health Centre IV with suspected malaria (</offsets><xref ref-type="fig" rid="BMJOPEN2013002759F1"><offsets xml_i="18838" xml_f="18846" txt_i="10277" txt_f="10285">figure 1</offsets></xref><offsets xml_i="18853" xml_f="18990" txt_i="10285" txt_f="10419">). Inclusion criteria are age 1–10 years, weight over 10 kg, fever (tympanic temperature &gt;38°C) or history of fever in the last 24 h, </offsets><italic><offsets xml_i="18998" xml_f="19010" txt_i="10419" txt_f="10431">P falciparum</offsets></italic><offsets xml_i="19019" xml_f="19413" txt_i="10431" txt_f="10819"> mono-infection with a parasite density &lt;5 00 000/µl and normal G6PD enzyme function. Exclusion criteria are evidence of severe illness/danger signs, known allergy to study medications, haemoglobin &lt;8 g/dl, started menstruation, pregnancy or breastfeeding, antimalarials taken within the last 2 days, primaquine taken within the last 4 weeks and blood transfusion within the last 90 days.</offsets></p><fig id="BMJOPEN2013002759F1" position="float"><label><offsets xml_i="19471" xml_f="19479" txt_i="10820" txt_f="10828">Figure 1</offsets></label><caption><p><offsets xml_i="19499" xml_f="19534" txt_i="10828" txt_f="10863">Enrolment and selection procedures.</offsets></p></caption><graphic xlink:href="bmjopen2013002759f01"></graphic></fig><p><offsets xml_i="19610" xml_f="19635" txt_i="10864" txt_f="10889">The fluorescent spot test</offsets><xref ref-type="bibr" rid="R38"><offsets xml_i="19667" xml_f="19669" txt_i="10889" txt_f="10891">38</offsets></xref><offsets xml_i="19676" xml_f="19882" txt_i="10891" txt_f="11097"> is used for G6PD screening. This test has a cut-off of approximately 20% enzyme function, below that, there is no fluorescence. The WHO classification defines severe G6PD deficiency as 10% enzyme function.</offsets><xref ref-type="bibr" rid="R39"><offsets xml_i="19914" xml_f="19916" txt_i="11097" txt_f="11099">39</offsets></xref></p></sec><sec id="s2d"><title><offsets xml_i="19954" xml_f="19994" txt_i="11101" txt_f="11141">Randomisation, blinding and intervention</offsets></title><p><offsets xml_i="20005" xml_f="20099" txt_i="11142" txt_f="11236">After enrolment (day 0), participants are randomised to a treatment arm stratified by gender (</offsets><xref ref-type="fig" rid="BMJOPEN2013002759F2"><offsets xml_i="20146" xml_f="20154" txt_i="11236" txt_f="11244">figure 2</offsets></xref><offsets xml_i="20161" xml_f="20630" txt_i="11244" txt_f="11713">). The study pharmacist selects sequential opaque envelopes (from either the male or the female pile). Each envelope contains a predetermined treatment assignment code. The study pharmacist is the only member of the clinic team not blinded to the treatment arm and is not involved in assessing patients or assigning outcomes. All study site staff who administer drugs, assess patients and process laboratory samples do not have access to the randomisation code breaker.</offsets></p><fig id="BMJOPEN2013002759F2" position="float"><label><offsets xml_i="20688" xml_f="20696" txt_i="11714" txt_f="11722">Figure 2</offsets></label><caption><p><offsets xml_i="20716" xml_f="20741" txt_i="11722" txt_f="11747">Participant flow diagram.</offsets></p></caption><graphic xlink:href="bmjopen2013002759f02"></graphic></fig><p><offsets xml_i="20817" xml_f="21975" txt_i="11748" txt_f="12903">All participants receive a 3 day course of artemether lumefantrine according to Ugandan national treatment guidelines for uncomplicated malaria. Participants are randomised to receive a placebo or a dose of 0.1, 0.4 or 0.75 mg/kg primaquine in addition to the AL treatment. The dose of primaquine/placebo is given at the same time as the fifth dose of AL, in the morning of day 2. To preserve the accuracy of lower weight-based doses, all primaquine doses are administered in aqueous solution and measured using a sterile syringe. The placebo is aqueous solution alone. All doses including placebo are mixed with glucose-based syrup that masks the colour and taste of primaquine. All treatments are directly observed. A snack with approximately 5 g of fat is administered prior to both AL and primaquine administration to optimise absorption of AL and minimise gastrointestinal side effects with primaquine. Participants are observed for 30 minutes; treatment is readministered in any case of vomiting within this period. Repeated vomiting (&gt;3 times) leads to exclusion from the study and treatment as complicated malaria according to national guidelines.</offsets></p></sec><sec id="s2e"><title><offsets xml_i="22006" xml_f="22028" txt_i="12905" txt_f="12927">Follow-up measurements</offsets></title><p><offsets xml_i="22039" xml_f="22420" txt_i="12928" txt_f="13309">Study participants are reviewed on days 0, 1, 2, 3, 7, 10, 14, 21 and 28 after enrolment or on any day of illness. On each of the scheduled visit days they are assessed clinically with standardised adverse event recording and blood samples are taken for microscopical detection of asexual parasites and gametocytes, molecular detection of gametocytes and haemoglobin measurements (</offsets><xref ref-type="table" rid="BMJOPEN2013002759TB1"><offsets xml_i="22470" xml_f="22477" txt_i="13309" txt_f="13316">table 1</offsets></xref><offsets xml_i="22484" xml_f="22486" txt_i="13316" txt_f="13318">).</offsets></p><table-wrap id="BMJOPEN2013002759TB1" position="float"><label><offsets xml_i="22552" xml_f="22559" txt_i="13319" txt_f="13326">Table 1</offsets></label><caption><p><offsets xml_i="22579" xml_f="22606" txt_i="13326" txt_f="13353">Summary of outcome measures</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead valign="bottom"><tr><th rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="22887" xml_f="22902" txt_i="13354" txt_f="13369">Outcome measure</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="22948" xml_f="22959" txt_i="13369" txt_f="13380">Description</offsets></th></tr></thead><tbody><tr><td colspan="3" rowspan="1"><offsets xml_i="23016" xml_f="23024" txt_i="13380" txt_f="13388">Efficacy</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23066" xml_f="23074" txt_i="13389" txt_f="13397"> Primary</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23107" xml_f="23156" txt_i="13398" txt_f="13447">Mean number of days to gametocyte clearance (GCT)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23189" xml_f="23413" txt_i="13448" txt_f="13672">Mean number of days per treatment arm for gametocytes to become undetectable using submicroscopic molecular testing methods (QT-NASBA). Reappearance of gametocytes after day 14 will be considered as re-infection and excluded</offsets></td></tr><tr><td rowspan="3" colspan="1"><offsets xml_i="23455" xml_f="23465" txt_i="13673" txt_f="13683"> Secondary</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23498" xml_f="23587" txt_i="13684" txt_f="13773">Mean (±SD) area under the curve of gametocyte density per day during 14 days of follow-up</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23620" xml_f="23733" txt_i="13774" txt_f="13887">Total number of gametocytes (measured by QT-NASBA) seen over follow-up, averaged per day of follow-up (days 0–14)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23775" xml_f="23818" txt_i="13888" txt_f="13931">Density of gametocytes on days 7, 10 and 14</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23851" xml_f="23939" txt_i="13932" txt_f="14020">Mean number of gametocytes (measured by QT-NASBA) per treatment arm on days 7, 10 and 14</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23981" xml_f="24053" txt_i="14021" txt_f="14093">Proportion (%) of participants with gametocytes on each day of follow-up</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24086" xml_f="24216" txt_i="14094" txt_f="14224">For each treatment arm, percentage of participants with gametocytes (measured by QT-NASBA) on each day of follow-up from days 0–14</offsets></td></tr><tr><td colspan="3" rowspan="1"><offsets xml_i="24258" xml_f="24264" txt_i="14225" txt_f="14231">Safety</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24306" xml_f="24314" txt_i="14232" txt_f="14240"> Primary</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24347" xml_f="24439" txt_i="14241" txt_f="14333">Mean (± SD) maximal fall (±) in Hb (haemoglobin, g/dl) from enrolment to day 28 of follow-up</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24472" xml_f="24603" txt_i="14334" txt_f="14465">Mean maximal greatest negative difference in Hb (measured by HemoCue) from enrolment value per treatment arm over 28 days follow-up</offsets></td></tr><tr><td rowspan="7" colspan="1"><offsets xml_i="24645" xml_f="24655" txt_i="14466" txt_f="14476"> Secondary</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24688" xml_f="24713" txt_i="14477" txt_f="14502">Follow-up day of Hb nadir</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24746" xml_f="24834" txt_i="14503" txt_f="14591">Mean day of follow-up (day 0–28) per treatment arm of lowest Hb measurement (by HemoCue)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24876" xml_f="24939" txt_i="14592" txt_f="14655">Maximal percentage fall in Hb level compared to enrolment value</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24972" xml_f="25091" txt_i="14656" txt_f="14775">Size of maximal Hb drop (by HemoCue) during follow-up (day 0–28) from enrolment value, divided by enrolment value, *100</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25133" xml_f="25194" txt_i="14776" txt_f="14834">Percentage of participants with Hb&lt;5 g/dl during follow-up</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25227" xml_f="25281" txt_i="14835" txt_f="14889">Percentage (number) per treatment arm during days 0–28</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25323" xml_f="25356" txt_i="14890" txt_f="14923">Requirement for blood transfusion</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25389" xml_f="25483" txt_i="14924" txt_f="15018">Percentage (number) of children receiving blood transfusion per treatment arm during days 0–28</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25525" xml_f="25548" txt_i="15019" txt_f="15042">Evidence of black urine</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25581" xml_f="25716" txt_i="15043" txt_f="15178">Percentage (number) of children with documented black/dark urine with urine dipstick positive for Hb per treatment arm during days 0–28</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25758" xml_f="25870" txt_i="15179" txt_f="15291">Incidence of serious adverse events by sign, symptom, laboratory parameter and relationship to taking study drug</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25903" xml_f="25957" txt_i="15292" txt_f="15346">Percentage (number) per treatment arm during days 0–28</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25999" xml_f="26061" txt_i="15347" txt_f="15409">Incidence of gastrointestinal symptoms after taking study drug</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26094" xml_f="26147" txt_i="15410" txt_f="15463">Percentage (number) per treatment arm during days 2–7</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="26197" xml_f="26316" txt_i="15464" txt_f="15583">GCT, gametocyte clearance time; Hb, haemoglobin; QT-NASBA, quantitative real-time nucleic acid sequence-based analysis.</offsets></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="26359" xml_f="27038" txt_i="15584" txt_f="16263">Blood smears from all visits are Giemsa-stained and 100 microscopic fields are screened for asexual parasites on days 0, 1, 2, 3, 7, 10, 14, 21 and 28. Asexual parasites are counted against 200 white blood cells (WBC) or, if fewer than 10 parasites are observed per 200 WBC, against 500 WBC. Gametocytes are recorded if observed during this screening process. On day 0, 100 microscopic fields are reread for gametocytes specifically. If gametocytes are observed, they are quantified against 500 WBC. All microscopy readings are performed by two independent microscopists, if they disagree on prevalence or if density results differ by more than 25%, a third reading is requested.</offsets></p><p><offsets xml_i="27045" xml_f="27206" txt_i="16264" txt_f="16425">Gametocytes are quantified on days 0, 2, 3, 7, 10 and 14 using quantitative real-time nucleic acid sequence-based analysis (QT-NASBA), detecting and quantifying </offsets><italic><offsets xml_i="27214" xml_f="27217" txt_i="16425" txt_f="16428">Pfs</offsets></italic><offsets xml_i="27226" xml_f="27462" txt_i="16428" txt_f="16664">25 mRNA. One hundred microlitres of finger prick blood is mixed with 900 µl L6 guanidine buffer (Severn Biotech, UK) and stored at −80°C until automatic nucleic acid extraction by MagNAPure (Roche) using commercial high-yield kits. The </offsets><italic><offsets xml_i="27470" xml_f="27473" txt_i="16664" txt_f="16667">Pfs</offsets></italic><offsets xml_i="27482" xml_f="27637" txt_i="16667" txt_f="16822">25 QT-NASBA is specific for mature gametocytes with a sensitivity of 0.01–0.1 gametocytes/µl of blood when 50 µl blood samples are used for RNA extraction.</offsets><xref ref-type="bibr" rid="R40"><offsets xml_i="27669" xml_f="27671" txt_i="16822" txt_f="16824">40</offsets></xref></p><p><offsets xml_i="27685" xml_f="28125" txt_i="16825" txt_f="17265">Haemoglobin is measured on days 0, 1, 2, 3, 7, 10, 14, 21 and 28 using HemoCue 201+ photometers (HemoCue; Angelholm, Sweden). At each follow-up visit, study staff assess participants in an objective manner according to a clinical record form and assessment for adverse events is conducted in a prospective, systematic fashion during all visits, including the enrolment visit (eg, vomiting post-AL). All data are double-entered in real time.</offsets></p></sec><sec id="s2f"><title><offsets xml_i="28156" xml_f="28177" txt_i="17267" txt_f="17288">Safety considerations</offsets></title><p><offsets xml_i="28188" xml_f="28317" txt_i="17289" txt_f="17418">A protocol was developed in order to standardise the detection, investigation and management of severe haemolysis in this trial (</offsets><xref ref-type="fig" rid="BMJOPEN2013002759F3"><offsets xml_i="28364" xml_f="28373" txt_i="17418" txt_f="17427">figures 3</offsets></xref><offsets xml_i="28380" xml_f="28385" txt_i="17427" txt_f="17432"> and </offsets><xref ref-type="fig" rid="BMJOPEN2013002759F4"><offsets xml_i="28432" xml_f="28433" txt_i="17432" txt_f="17433">4</offsets></xref><offsets xml_i="28440" xml_f="28629" txt_i="17433" txt_f="17622">). A Data Safety Monitoring Board (DSMB) has been installed; clinically relevant haemolytic events, hospital admissions, blood transfusions and deaths are reported within 72 h to this DSMB.</offsets></p><fig id="BMJOPEN2013002759F3" position="float"><label><offsets xml_i="28687" xml_f="28695" txt_i="17623" txt_f="17631">Figure 3</offsets></label><caption><p><offsets xml_i="28715" xml_f="28767" txt_i="17631" txt_f="17683">Procedure for investigation of suspected haemolysis.</offsets></p></caption><graphic xlink:href="bmjopen2013002759f03"></graphic></fig><fig id="BMJOPEN2013002759F4" position="float"><label><offsets xml_i="28894" xml_f="28902" txt_i="17684" txt_f="17692">Figure 4</offsets></label><caption><p><offsets xml_i="28922" xml_f="28961" txt_i="17692" txt_f="17731">Procedure for management of haemolysis.</offsets></p></caption><graphic xlink:href="bmjopen2013002759f04"></graphic></fig></sec><sec id="s2g"><title><offsets xml_i="29061" xml_f="29083" txt_i="17733" txt_f="17755">Ethical considerations</offsets></title><p><offsets xml_i="29094" xml_f="29827" txt_i="17756" txt_f="18489">The study protocol and informed consent forms were approved by the Makerere University School of Medicine Research Ethics Committee (protocol 2011–210), the Uganda National Council of Science and Technology (protocol HS1056) and the London School of Hygiene and Tropical Medicine research ethics committee (protocol 5987). The Ugandan National Drug Authority approved the protocol and importation of primaquine for the purposes of the study. The DSMB and Trial Advisory Committee for the study agreed to meet at predetermined stages of the study. Before the study began, local community stakeholders (including village health team and local council members) in Walukuba were consulted and a community advisory board meeting was held.</offsets></p></sec><sec id="s2h"><title><offsets xml_i="29858" xml_f="29869" txt_i="18491" txt_f="18502">Sample size</offsets></title><p><offsets xml_i="29880" xml_f="30264" txt_i="18503" txt_f="18887">For efficacy, the sample size calculation is based on non-inferiority of each of the two test dose arms to the comparator arm, the WHO-recommended dose of primaquine, 0.75 mg/kg. The primary outcome measure is number of days to gametocyte clearance. The addition of primaquine (0.75 mg/kg) to ACT in Tanzania reduced the time to gametocyte clearance from 28.6 to 6.3 days (SD 6 days).</offsets><xref ref-type="bibr" rid="R41"><offsets xml_i="30296" xml_f="30298" txt_i="18887" txt_f="18889">41</offsets></xref><offsets xml_i="30305" xml_f="30719" txt_i="18889" txt_f="19303"> Allowing for a 10% loss to follow-up, a sample size of 120/arm will provide over 80% power at the 0.05 significance level to detect non-inferiority to the standard arm with a non-inferiority margin of 2.5 days, which was considered to be a clinically relevant reduction in gametocyte clearance time. This sample size also allows for an analysis of superiority of the efficacy of the two test dose arms to placebo.</offsets></p><p><offsets xml_i="30726" xml_f="30896" txt_i="19304" txt_f="19474">For safety, the sample size calculation is based on superiority of each of the two test dose arms to the comparator arm (0.75 mg/kg). For this comparator arm, Shekalaghe </offsets><italic><offsets xml_i="30904" xml_f="30909" txt_i="19474" txt_f="19479">et al</offsets></italic><xref ref-type="bibr" rid="R34"><offsets xml_i="30950" xml_f="30952" txt_i="19479" txt_f="19481">34</offsets></xref><offsets xml_i="30959" xml_f="31254" txt_i="19481" txt_f="19776"> found an overall mean absolute drop in haemoglobin by day 7 after treatment of 0.6 g/dl (SD 1.5). Therefore, with 80% power and at the 0.05 significance level, a sample size of 99 would be required to detect a difference in mean maximal drop in haemoglobin between treatment groups of 0.6 g/dl.</offsets></p></sec><sec id="s2i"><title><offsets xml_i="31285" xml_f="31298" txt_i="19778" txt_f="19791">Data analysis</offsets></title><p><offsets xml_i="31309" xml_f="31480" txt_i="19792" txt_f="19963">Data will be double entered in Microsoft Access and imported into Stata V.12.0 (Statacorp Ltd, Texas, USA). All efficacy analyses will be based on gametocyte detection by </offsets><italic><offsets xml_i="31488" xml_f="31491" txt_i="19963" txt_f="19966">Pfs</offsets></italic><offsets xml_i="31500" xml_f="31622" txt_i="19966" txt_f="20088">25 QT-NASBA. Gametocyte density on days 7, 10 and 14 will be compared with the comparator arm (0.75 mg primaquine/kg) by χ</offsets><sup><offsets xml_i="31627" xml_f="31628" txt_i="20088" txt_f="20089">2</offsets></sup><offsets xml_i="31634" xml_f="31818" txt_i="20089" txt_f="20273"> test. The mean duration of gametocyte carriage and 95% CI will be estimated in each treatment arm and compared with the comparator arm using a previously validated mathematical model.</offsets><xref ref-type="bibr" rid="R42"><offsets xml_i="31850" xml_f="31852" txt_i="20273" txt_f="20275">42</offsets></xref><italic><offsets xml_i="31867" xml_f="31872" txt_i="20275" txt_f="20280">et al</offsets></italic><xref ref-type="bibr" rid="R43"><offsets xml_i="31913" xml_f="31915" txt_i="20280" txt_f="20282">43</offsets></xref><offsets xml_i="31922" xml_f="32073" txt_i="20282" txt_f="20433"> For individuals who are gametocyte positive at enrolment, Kaplan-Meier survival analysis will be used to compare the decline in gametocyte prevalence.</offsets></p><p><offsets xml_i="32080" xml_f="32354" txt_i="20434" txt_f="20708">The primary safety outcome, mean maximal fall in haemoglobin concentration during 28 days of follow-up will be assessed for each treatment arm. Pair-wise comparisons will be made between each of the treatment arms and compared with the comparator arm using unpaired t tests.</offsets></p></sec></sec><sec sec-type="discussion" id="s3"><title><offsets xml_i="32412" xml_f="32422" txt_i="20711" txt_f="20721">Discussion</offsets></title><p><offsets xml_i="32433" xml_f="32914" txt_i="20722" txt_f="21203">In the 2010 edition of the Guidelines for the Treatment of Malaria, the WHO recommends that a single dose of 0.75 mg/kg primaquine is added to ACT in malaria elimination programmes and for epidemic control, provided the risks of haemolysis in G6PD-deficient patients are considered. This guidance was recently updated to recommend a lower dose of 0.25 mg/kg primaquine without G6PD testing for new malaria elimination programmes and to prevent the spread of artemisinin resistance.</offsets><xref ref-type="bibr" rid="R31"><offsets xml_i="32946" xml_f="32948" txt_i="21203" txt_f="21205">31</offsets></xref><offsets xml_i="32955" xml_f="33109" txt_i="21205" txt_f="21359"> The revision was based largely on grey literature and historical data rather than on recent clinical trials and few of the data are in the public domain.</offsets><xref ref-type="bibr" rid="R44"><offsets xml_i="33141" xml_f="33143" txt_i="21359" txt_f="21361">44</offsets></xref><offsets xml_i="33150" xml_f="33478" txt_i="21361" txt_f="21689"> There have been no formal dose-finding studies using contemporary tools and standards for the measurement of drug efficacy and safety for the combination of ACTs and primaquine. In the current study, we aim to provide these urgently needed efficacy data and provide safety data for individuals with normal G6PD enzyme function.</offsets></p><p><offsets xml_i="33485" xml_f="33689" txt_i="21690" txt_f="21894">Relatively few trials have been designed specifically to test gametocytocidal drugs in vivo. Standardised protocols and trial designs for assessing the efficacy of drugs targeted against asexual parasites</offsets><xref ref-type="bibr" rid="R45"><offsets xml_i="33721" xml_f="33723" txt_i="21894" txt_f="21896">45</offsets></xref><offsets xml_i="33730" xml_f="33731" txt_i="21896" txt_f="21897">
</offsets><xref ref-type="bibr" rid="R46"><offsets xml_i="33763" xml_f="33765" txt_i="21897" txt_f="21899">46</offsets></xref><offsets xml_i="33772" xml_f="34054" txt_i="21899" txt_f="22181"> are not suitable to assess gametocytocidal drugs, where the main outcome is transmission-blocking activity rather than clinical or parasitological cure. There is no agreement on the best tools to quantify gametocyte carriage. Many trials have used microscopy to measure gametocytes</offsets><xref ref-type="bibr" rid="R26"><offsets xml_i="34086" xml_f="34089" txt_i="22181" txt_f="22184">26–</offsets></xref><offsets xml_i="34096" xml_f="34097" txt_i="22184" txt_f="22185">–</offsets><xref ref-type="bibr" rid="R28"><offsets xml_i="34129" xml_f="34131" txt_i="22185" txt_f="22187">28</offsets></xref><offsets xml_i="34138" xml_f="34139" txt_i="22187" txt_f="22188">
</offsets><xref ref-type="bibr" rid="R47"><offsets xml_i="34171" xml_f="34173" txt_i="22188" txt_f="22190">47</offsets></xref><offsets xml_i="34180" xml_f="34181" txt_i="22190" txt_f="22191">
</offsets><xref ref-type="bibr" rid="R48"><offsets xml_i="34213" xml_f="34215" txt_i="22191" txt_f="22193">48</offsets></xref><offsets xml_i="34222" xml_f="34328" txt_i="22193" txt_f="22299"> while it has been known for decades that microscopy is notoriously insensitive for detecting gametocytes.</offsets><xref ref-type="bibr" rid="R49"><offsets xml_i="34360" xml_f="34362" txt_i="22299" txt_f="22301">49</offsets></xref><offsets xml_i="34369" xml_f="34458" txt_i="22301" txt_f="22390"> Gametocytes typically circulate at densities that are ≤1% of asexual parasite densities.</offsets><xref ref-type="bibr" rid="R16"><offsets xml_i="34490" xml_f="34492" txt_i="22390" txt_f="22392">16</offsets></xref><offsets xml_i="34499" xml_f="34500" txt_i="22392" txt_f="22393">
</offsets><xref ref-type="bibr" rid="R50"><offsets xml_i="34532" xml_f="34534" txt_i="22393" txt_f="22395">50</offsets></xref><offsets xml_i="34541" xml_f="34781" txt_i="22395" txt_f="22635"> Nevertheless, gametocytes are often simply recorded while screening for asexual parasites. If slides are specifically read for gametocytes, the number of microscopic fields that is screened is mostly the same as that for asexual parasites.</offsets><xref ref-type="bibr" rid="R51"><offsets xml_i="34813" xml_f="34815" txt_i="22635" txt_f="22637">51</offsets></xref><offsets xml_i="34822" xml_f="34952" txt_i="22637" txt_f="22767"> As a consequence, gametocytes measured microscopically by routine underestimate the total gametocyte prevalence by up to 10-fold.</offsets><xref ref-type="bibr" rid="R16"><offsets xml_i="34984" xml_f="34986" txt_i="22767" txt_f="22769">16</offsets></xref><offsets xml_i="34993" xml_f="34994" txt_i="22769" txt_f="22770">
</offsets><xref ref-type="bibr" rid="R17"><offsets xml_i="35026" xml_f="35028" txt_i="22770" txt_f="22772">17</offsets></xref><offsets xml_i="35035" xml_f="35036" txt_i="22772" txt_f="22773">
</offsets><xref ref-type="bibr" rid="R21"><offsets xml_i="35068" xml_f="35070" txt_i="22773" txt_f="22775">21</offsets></xref><offsets xml_i="35077" xml_f="35078" txt_i="22775" txt_f="22776">
</offsets><xref ref-type="bibr" rid="R22"><offsets xml_i="35110" xml_f="35112" txt_i="22776" txt_f="22778">22</offsets></xref><offsets xml_i="35119" xml_f="35349" txt_i="22778" txt_f="23008"> In the current study, gametocytes are quantified with the most widely used quantitative molecular gametocyte detection method, QT-NASBA that has an estimated sensitivity of 0.01–0.1 gametocytes/µl blood in the blood sample taken.</offsets><xref ref-type="bibr" rid="R40"><offsets xml_i="35381" xml_f="35383" txt_i="23008" txt_f="23010">40</offsets></xref><offsets xml_i="35390" xml_f="35619" txt_i="23010" txt_f="23239"> The use of this sensitive molecular method will increase the power of our efficacy estimates since up to 90% of symptomatic malaria patients may harbour (submicroscopic) gametocyte densities prior to the initiation of treatment.</offsets><xref ref-type="bibr" rid="R16"><offsets xml_i="35651" xml_f="35653" txt_i="23239" txt_f="23241">16</offsets></xref></p><p><offsets xml_i="35667" xml_f="36053" txt_i="23242" txt_f="23628">Gametocyte density is associated with the likelihood of mosquito infection and some of the lowest gametocyte densities may therefore be unlikely to result in mosquito infections. In general, there are limitations to which gametocyte prevalence or density can be used to predict mosquito infection rates. The fitness or infectivity of gametocytes is variable, especially after treatment.</offsets><xref ref-type="bibr" rid="R19"><offsets xml_i="36085" xml_f="36087" txt_i="23628" txt_f="23630">19</offsets></xref><offsets xml_i="36094" xml_f="36095" txt_i="23630" txt_f="23631">
</offsets><xref ref-type="bibr" rid="R52"><offsets xml_i="36127" xml_f="36129" txt_i="23631" txt_f="23633">52</offsets></xref><offsets xml_i="36136" xml_f="36137" txt_i="23633" txt_f="23634">
</offsets><xref ref-type="bibr" rid="R53"><offsets xml_i="36169" xml_f="36171" txt_i="23634" txt_f="23636">53</offsets></xref><offsets xml_i="36178" xml_f="36323" txt_i="23636" txt_f="23781"> Very early studies demonstrated that primaquine may render gametocytes non-infectious several days before they are cleared from the circulation.</offsets><xref ref-type="bibr" rid="R30"><offsets xml_i="36355" xml_f="36357" txt_i="23781" txt_f="23783">30</offsets></xref><offsets xml_i="36364" xml_f="36365" txt_i="23783" txt_f="23784">
</offsets><xref ref-type="bibr" rid="R54"><offsets xml_i="36397" xml_f="36399" txt_i="23784" txt_f="23786">54</offsets></xref><offsets xml_i="36406" xml_f="36407" txt_i="23786" txt_f="23787">
</offsets><xref ref-type="bibr" rid="R55"><offsets xml_i="36439" xml_f="36441" txt_i="23787" txt_f="23789">55</offsets></xref><offsets xml_i="36448" xml_f="36661" txt_i="23789" txt_f="24002"> The only approach to directly measure transmission-blocking potential involves assessing the infectiousness of the participant's blood to mosquitoes using the membrane feeding assay or direct skin feeding assays,</offsets><xref ref-type="bibr" rid="R56"><offsets xml_i="36693" xml_f="36695" txt_i="24002" txt_f="24004">56</offsets></xref><offsets xml_i="36702" xml_f="36754" txt_i="24004" txt_f="24056"> the latter being described by early malariologists.</offsets><xref ref-type="bibr" rid="R57"><offsets xml_i="36786" xml_f="36788" txt_i="24056" txt_f="24058">57</offsets></xref><offsets xml_i="36795" xml_f="36796" txt_i="24058" txt_f="24059">
</offsets><xref ref-type="bibr" rid="R58"><offsets xml_i="36828" xml_f="36830" txt_i="24059" txt_f="24061">58</offsets></xref><offsets xml_i="36837" xml_f="37267" txt_i="24061" txt_f="24491"> However, the capacity for mosquito feeding assays is not widely available and repeated assessments of infectiousness on the same patients have never been performed as part of clinical trials. This is partly because of ethical concerns related to repeated venous bleeding in young children, and partly because of the complexity of mosquito husbandry when large numbers of mosquitoes are required for robust transmission estimates.</offsets><xref ref-type="bibr" rid="R59"><offsets xml_i="37299" xml_f="37301" txt_i="24491" txt_f="24493">59</offsets></xref><offsets xml_i="37308" xml_f="37533" txt_i="24493" txt_f="24718"> In the absence of biomarkers, using the prevalence and density of gametocytes after treatment is the most pragmatic approach to assess the transmission-blocking efficacy of drugs across a variety of malaria endemic settings.</offsets></p><p><offsets xml_i="37540" xml_f="37681" txt_i="24719" txt_f="24860">To assess the safety of the 8-aminoquinoline drugs, there must be a clear definition of the risk of haemolysis and how it should be measured.</offsets><xref ref-type="bibr" rid="R31"><offsets xml_i="37713" xml_f="37715" txt_i="24860" txt_f="24862">31</offsets></xref><offsets xml_i="37722" xml_f="37723" txt_i="24862" txt_f="24863">
</offsets><xref ref-type="bibr" rid="R60"><offsets xml_i="37755" xml_f="37757" txt_i="24863" txt_f="24865">60</offsets></xref><offsets xml_i="37764" xml_f="38259" txt_i="24865" txt_f="25360"> The safety profile may best be defined by the incidence of endpoints that could compromise health, such as signs of severe haemolysis, and the need for interventions such as haematinic drug administration, hospitalisation or blood transfusion. These events, however, are rare and changes in haemoglobin concentration may be a more sensitive primary safety outcome for standard clinical trials. In a recent Cochrane review of randomised controlled trials of primaquine's efficacy, only one trial</offsets><xref ref-type="bibr" rid="R25"><offsets xml_i="38291" xml_f="38293" txt_i="25360" txt_f="25362">25</offsets></xref><offsets xml_i="38300" xml_f="38375" txt_i="25362" txt_f="25437"> was found to have measured the haemoglobin concentration to assess safety.</offsets><xref ref-type="bibr" rid="R61"><offsets xml_i="38407" xml_f="38409" txt_i="25437" txt_f="25439">61</offsets></xref><offsets xml_i="38416" xml_f="38989" txt_i="25439" txt_f="26012"> In this current study, clinically relevant safety endpoints have been selected and a standardised procedure is in place for the investigation and management of severe haemolysis. A shortcoming of the current study is that safety data are most urgently needed in the most vulnerable group, G6PD-deficient individuals. For ethical reasons this group was excluded. The authors consider that the priority is first to determine the minimal effective dose in a G6PD normal population before G6PD-deficient individuals are exposed to this low dose of primaquine to assess safety.</offsets></p><p><offsets xml_i="38996" xml_f="39473" txt_i="26013" txt_f="26490">The ultimate evidence for a beneficial role of primaquine in reducing malaria transmission would come from trials assessing the effect of the drug on measures of community-level transmission. Once a safe and efficacious dose of primaquine in combination with ACTs is established, the next step involves designing these community trials. Treatment of symptomatic cases could play an important role in reducing the spread of (resistant) malaria strains from symptomatic patients.</offsets><xref ref-type="bibr" rid="R62"><offsets xml_i="39505" xml_f="39507" txt_i="26490" txt_f="26492">62</offsets></xref><offsets xml_i="39514" xml_f="39607" txt_i="26492" txt_f="26585"> However, because of the large pool of asymptomatic parasite carriers in all endemic settings</offsets><xref ref-type="bibr" rid="R63"><offsets xml_i="39639" xml_f="39641" txt_i="26585" txt_f="26587">63</offsets></xref><offsets xml_i="39648" xml_f="39971" txt_i="26587" txt_f="26910"> and their importance in defining transmission potential, any effect of primaquine on community-wide transmission will be limited if administration is restricted to symptomatic cases. Other strategies such as pro-active screening and treatment and (focal) mass drug administration may have a larger impact in some settings.</offsets><xref ref-type="bibr" rid="R64"><offsets xml_i="40003" xml_f="40005" txt_i="26910" txt_f="26912">64</offsets></xref><offsets xml_i="40012" xml_f="40140" txt_i="26912" txt_f="27040"> This trial forms the starting point for defining the optimal dose of primaquine for use in transmission-blocking interventions.</offsets></p></sec><sec sec-type="supplementary-material"><title><offsets xml_i="40196" xml_f="40218" txt_i="27042" txt_f="27064">Supplementary Material</offsets></title><supplementary-material id="d35e241" content-type="local-data"><caption><title><offsets xml_i="40305" xml_f="40324" txt_i="27065" txt_f="27084">Author's manuscript</offsets></title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="bmjopen-2013-002759.draft_revisions.pdf"></media></supplementary-material></sec></body><back><ack><p>The authors would like to thank staff at the Infectious Diseases Research Collaboration (IDRC) in Uganda, notably, Mr Moses Kiggundu, Dr Catherine Maiteki-Sebuguzi, the members of the Programme for Resistance, Immunology, Surveillance and Modelling of Malaria in Uganda (PRISM) and the ACT PRIME and PROCESS research teams and also Ms Carolynne Stanley for logistical support at the London School of Hygiene and Tropical Medicine.</p></ack><fn-group><fn><p><bold>Contributors:</bold> ACE, SGS, SY, NJW, TB and CD have conceived and designed the study and participated in logistical planning together with EW and MK. EW provided the statistical support for the sample size estimates and the design of the statistical analysis. TB provided the expertise for submicroscopic gametocyte measurement. ACE organised the ethical applications, community sensitisation and study implementation and wrote the manuscript together with TB and CD. All authors have read and approved the final manuscript.</p></fn><fn><p><bold>Funding:</bold> This study is funded by ACE's Clinical Fellowship from the Wellcome Trust of Great Britain (grant #090558/Z/09/Z).</p></fn><fn><p><bold>Competing interests:</bold> None.</p></fn><fn><p><bold>Ethics approval:</bold> Makerere University School of Medicine Research Ethics Committee (protocol 2011-210), the Uganda National Council of Science and Technology (protocol HS1056) and the London School of Hygiene and Tropical Medicine research ethics committee (protocol 5987).</p></fn><fn><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn><p><bold>Trial status:</bold> Recruitment began on 6 December 2011. The trial is going on .</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>JT</given-names></name><name><surname>Hollingsworth</surname><given-names>TD</given-names></name><name><surname>Okell</surname><given-names>LC</given-names></name><etal></etal></person-group>
<article-title>Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies</article-title>. <source>PLoS Med</source>
<year>2010</year>;<volume>7</volume> doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1000324">10.1371/journal.pmed.1000324</ext-link>
<comment>(published Online First: Epub Date)</comment></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Yi</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Artemisinin resistance in Plasmodium falciparum malaria</article-title>. <source>N Engl J Med</source>
<year>2009</year>;<volume>361</volume>:<fpage>455</fpage>–<lpage>67</lpage><pub-id pub-id-type="pmid">19641202</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Sreng</surname><given-names>S</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study</article-title>. <source>Lancet Infect Dis</source>
<year>2012</year>;<volume>12</volume>:<fpage>851</fpage>–<lpage>8</lpage>
<comment>doi: S1473-3099(12)70181-0 [pii] 10.1016/S1473-3099(12)70181-0 (published Online First: Epub Date)</comment><pub-id pub-id-type="pmid">22940027</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>J</given-names></name><name><surname>St Laurent</surname><given-names>B</given-names></name><name><surname>Lobo</surname><given-names>NF</given-names></name><etal></etal></person-group>
<article-title>Novel vectors of malaria parasites in the Western highlands of Kenya</article-title>. <source>Emerg Infect Dis</source>
<year>2012</year>;<volume>18</volume>:<fpage>1547</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">22932762</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riehle</surname><given-names>MM</given-names></name><name><surname>Guelbeogo</surname><given-names>WM</given-names></name><name><surname>Gneme</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>A cryptic subgroup of Anopheles gambiae is highly susceptible to human malaria parasites</article-title>. <source>Science</source>
<year>2011</year>;<volume>331</volume>:<fpage>596</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">21292978</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trung</surname><given-names>HD</given-names></name><name><surname>Bortel</surname><given-names>WV</given-names></name><name><surname>Sochantha</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Behavioural heterogeneity of Anopheles species in ecologically different localities in Southeast Asia: a challenge for vector control</article-title>. <source>Trop Med Int Health</source>
<year>2005</year>;<volume>10</volume>:<fpage>251</fpage>–<lpage>62</lpage><pub-id pub-id-type="pmid">15730510</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dondorp</surname><given-names>AM</given-names></name></person-group>
<article-title>Editorial commentary: single-dose primaquine as gametocytocidal treatment in patients with uncomplicated falciparum malaria</article-title>. <source>Clin Infect Dis</source>
<year>2013</year>;<volume>56</volume>:<fpage>694</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">23175557</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>PL</given-names></name><name><surname>Brown</surname><given-names>G</given-names></name><name><surname>Arevalo-Herrera</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>A research agenda to underpin malaria eradication</article-title>. <source>PLoS Med</source>
<year>2011</year>;<volume>8</volume>:<fpage>e1000406</fpage><pub-id pub-id-type="pmid">21311579</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Field</surname><given-names>JW</given-names></name><name><surname>Shute</surname><given-names>P</given-names></name></person-group>
<comment>The microscopic diagnosis of human malaria. II. A morphological study of the erythrocytic parasites. Studies from the Institute for Medical Research, Federated Malay States 1956</comment></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smalley</surname><given-names>ME</given-names></name><name><surname>Abdalla</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name></person-group>
<article-title>The distribution of Plasmodium falciparum in the peripheral blood and bone marrow of Gambian children</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<year>1981</year>;<volume>75</volume>:<fpage>103</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">7022784</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>NJ</given-names></name><name><surname>Hall</surname><given-names>BS</given-names></name><name><surname>Obiero</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>A model for sequestration of the transmission stages of Plasmodium falciparum: adhesion of gametocyte-infected erythrocytes to human bone marrow cells</article-title>. <source>Infect Immun</source>
<year>2000</year>;<volume>68</volume>:<fpage>3455</fpage>–<lpage>62</lpage><pub-id pub-id-type="pmid">10816498</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>JGRA</given-names></name></person-group>
<article-title>The structure and development of Plasmodium falciparum gametocytes in the internal organs and peripheral circulation</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<year>1935</year>;<volume>29</volume>:<fpage>31</fpage>–<lpage>4</lpage></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smalley</surname><given-names>ME</given-names></name><name><surname>Sinden</surname><given-names>RE</given-names></name></person-group>
<article-title>Plasmodium falciparum gametocytes: their longevity and infectivity</article-title>. <source>Parasitology</source>
<year>1977</year>;<volume>74</volume>:<fpage>1</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">320542</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lensen</surname><given-names>A</given-names></name><name><surname>Bril</surname><given-names>A</given-names></name><name><surname>van de Vegte</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Plasmodium falciparum: infectivity of cultured, synchronized gametocytes to mosquitoes</article-title>. <source>Exp Parasitol</source>
<year>1999</year>;<volume>91</volume>:<fpage>101</fpage>–<lpage>3</lpage><pub-id pub-id-type="pmid">9920049</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adjalley</surname><given-names>SH</given-names></name><name><surname>Johnston</surname><given-names>GL</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2011</year>;<volume>108</volume>:<fpage>E1214</fpage>–<lpage>23</lpage><pub-id pub-id-type="pmid">22042867</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousema</surname><given-names>T</given-names></name><name><surname>Drakeley</surname><given-names>C</given-names></name></person-group>
<article-title>Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination</article-title>. <source>Clin Microbiol Rev</source>
<year>2011</year>;<volume>24</volume>:<fpage>377</fpage>–<lpage>410</lpage><pub-id pub-id-type="pmid">21482730</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousema</surname><given-names>JT</given-names></name><name><surname>Schneider</surname><given-names>P</given-names></name><name><surname>Gouagna</surname><given-names>LC</given-names></name><etal></etal></person-group>
<article-title>Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum</article-title>. <source>J Infect Dis</source>
<year>2006</year>;<volume>193</volume>:<fpage>1151</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">16544256</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>E</given-names></name><name><surname>Mackinnon</surname><given-names>MJ</given-names></name><name><surname>Abdel-Muhsin</surname><given-names>AM</given-names></name><etal></etal></person-group>
<article-title>Increased density but not prevalence of gametocytes following drug treatment of Plasmodium falciparum</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<year>2006</year>;<volume>100</volume>:<fpage>176</fpage>–<lpage>83</lpage><pub-id pub-id-type="pmid">16257026</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Targett</surname><given-names>G</given-names></name><name><surname>Drakeley</surname><given-names>C</given-names></name><name><surname>Jawara</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae</article-title>. <source>J Infect Dis</source>
<year>2001</year>;<volume>183</volume>:<fpage>1254</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">11262208</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drakeley</surname><given-names>CJ</given-names></name><name><surname>Jawara</surname><given-names>M</given-names></name><name><surname>Targett</surname><given-names>GA</given-names></name><etal></etal></person-group>
<article-title>Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes</article-title>. <source>Trop Med Int Health</source>
<year>2004</year>;<volume>9</volume>:<fpage>53</fpage>–<lpage>61</lpage><pub-id pub-id-type="pmid">14728607</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>P</given-names></name><name><surname>Bousema</surname><given-names>T</given-names></name><name><surname>Omar</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>(Sub)microscopic Plasmodium falciparum gametocytaemia in Kenyan children after treatment with sulphadoxine-pyrimethamine monotherapy or in combination with artesunate</article-title>. <source>Int J Parasitol</source>
<year>2006</year>;<volume>36</volume>:<fpage>403</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">16500657</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mens</surname><given-names>PF</given-names></name><name><surname>Sawa</surname><given-names>P</given-names></name><name><surname>van Amsterdam</surname><given-names>SM</given-names></name><etal></etal></person-group>
<article-title>A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya</article-title>. <source>Malar J</source>
<year>2008</year>;<volume>7</volume>:<fpage>237</fpage><pub-id pub-id-type="pmid">19017387</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouedraogo</surname><given-names>AL</given-names></name><name><surname>Bousema</surname><given-names>T</given-names></name><name><surname>Schneider</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Substantial contribution of submicroscopical Plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission</article-title>. <source>PLoS ONE</source>
<year>2009</year>;<volume>4</volume>:<fpage>e8410</fpage><pub-id pub-id-type="pmid">20027314</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tekwani</surname><given-names>BL</given-names></name><name><surname>Walker</surname><given-names>LA</given-names></name></person-group>
<article-title>8-Aminoquinolines: future role as antiprotozoal drugs</article-title>. <source>Curr Opin Infect Dis</source>
<year>2006</year>;<volume>19</volume>:<fpage>623</fpage>–<lpage>31</lpage><pub-id pub-id-type="pmid">17075340</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shekalaghe</surname><given-names>S</given-names></name><name><surname>Drakeley</surname><given-names>C</given-names></name><name><surname>Gosling</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate</article-title>. <source>PLoS ONE</source>
<year>2007</year>;<volume>2</volume>:<fpage>e1023</fpage><pub-id pub-id-type="pmid">17925871</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutanto</surname><given-names>I</given-names></name><name><surname>Suprijanto</surname><given-names>S</given-names></name><name><surname>Kosasih</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South Sumatra, Western Indonesia: an open-label, randomized, controlled trial</article-title>. <source>Clin Infect Dis</source>
<year>2012</year>;<volume>56</volume>:<fpage>685</fpage>–<lpage>93</lpage> doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cid/cis959">10.1093/cid/cis959</ext-link>
<comment>[published Online First: Epub Date]</comment><pub-id pub-id-type="pmid">23175563</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smithuis</surname><given-names>F</given-names></name><name><surname>Kyaw</surname><given-names>MK</given-names></name><name><surname>Phe</surname><given-names>O</given-names></name><etal></etal></person-group>
<article-title>Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial</article-title>. <source>Lancet Infect Dis</source>
<year>2010</year>;<volume>10</volume>:<fpage>673</fpage>–<lpage>81</lpage><pub-id pub-id-type="pmid">20832366</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name><surname>Chotivanich</surname><given-names>K</given-names></name><name><surname>Chantra</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria</article-title>. <source>Antimicrob Agents Chemother</source>
<year>2004</year>;<volume>48</volume>:<fpage>1329</fpage>–<lpage>34</lpage><pub-id pub-id-type="pmid">15047537</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alving</surname><given-names>AS</given-names></name><name><surname>Johnson</surname><given-names>CF</given-names></name><name><surname>Tarlov</surname><given-names>AR</given-names></name><etal></etal></person-group>
<article-title>Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report</article-title>. <source>Bull World Health Organ</source>
<year>1960</year>;<volume>22</volume>:<fpage>621</fpage>–<lpage>31</lpage><pub-id pub-id-type="pmid">13793053</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>RW</given-names></name><name><surname>Bray</surname><given-names>RS</given-names></name></person-group>
<article-title>The effect of a single dose of primaquine on the gametocytes, gametogony and sporogony of Laverania falciparum</article-title>. <source>Bull World Health Organ</source>
<year>1961</year>;<volume>24</volume>:<fpage>451</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">13689019</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Qiao</surname><given-names>LG</given-names></name><name><surname>Qi</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common</article-title>. <source>Malar J</source>
<year>2012</year>;<volume>11</volume>:<fpage>418</fpage><pub-id pub-id-type="pmid">23237606</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charles</surname><given-names>LJ</given-names></name></person-group>
<article-title>Observations on the haemolytic effect of primaquine in 100 Ghanaian children</article-title>. <source>Ann Trop Med Parasitol</source>
<year>1960</year>;<volume>54</volume>:<fpage>460</fpage>–<lpage>70</lpage><pub-id pub-id-type="pmid">13692485</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reeve</surname><given-names>PA</given-names></name><name><surname>Toaliu</surname><given-names>H</given-names></name><name><surname>Kaneko</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Acute intravascular haemolysis in Vanuatu following a single dose of primaquine in individuals with glucose-6-phosphate dehydrogenase deficiency</article-title>. <source>J Trop Med Hyg</source>
<year>1992</year>;<volume>95</volume>:<fpage>349</fpage>–<lpage>51</lpage><pub-id pub-id-type="pmid">1404560</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shekalaghe</surname><given-names>SA</given-names></name><name><surname>ter Braak</surname><given-names>R</given-names></name><name><surname>Daou</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title></article-title>. <source>Antimicrob Agents Chemother</source>
<year>2010</year>;<volume>54</volume>:<fpage>1762</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">20194698</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Socheat</surname><given-names>D</given-names></name><name><surname>Tan</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine</article-title>. <source>Malar J</source>
<year>2010</year>;<volume>9</volume>:<fpage>57</fpage><pub-id pub-id-type="pmid">20175930</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Sayed</surname><given-names>B</given-names></name><name><surname>El-Zaki</surname><given-names>SE</given-names></name><name><surname>Babiker</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>A randomized open-label trial of artesunate-sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan</article-title>. <source>PLoS One</source>
<year>2007</year>;<volume>2</volume>:<fpage>e1311</fpage><pub-id pub-id-type="pmid">18074034</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okello</surname><given-names>PE</given-names></name><name><surname>Van Bortel</surname><given-names>W</given-names></name><name><surname>Byaruhanga</surname><given-names>AM</given-names></name><etal></etal></person-group>
<article-title>Variation in malaria transmission intensity in seven sites throughout Uganda</article-title>. <source>Am J Trop Med Hyg</source>
<year>2006</year>;<volume>75</volume>:<fpage>219</fpage>–<lpage>25</lpage><pub-id pub-id-type="pmid">16896122</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>E</given-names></name><name><surname>Mitchell</surname><given-names>M</given-names></name></person-group>
<article-title>Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency</article-title>. <source>Blood</source>
<year>1968</year>;<volume>32</volume>:<fpage>816</fpage>–<lpage>18</lpage><pub-id pub-id-type="pmid">4386875</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>E</given-names></name><name><surname>Duparc</surname><given-names>S</given-names></name><name><surname>Group</surname><given-names>GPDW</given-names></name></person-group>
<article-title>Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development</article-title>. <source>Am J Trop Med Hyg</source>
<year>2007</year>;<volume>77</volume>:<fpage>779</fpage>–<lpage>89</lpage><pub-id pub-id-type="pmid">17978087</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>P</given-names></name><name><surname>Schoone</surname><given-names>G</given-names></name><name><surname>Schallig</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Quantification of Plasmodium falciparum gametocytes in differential stages of development by quantitative nucleic acid sequence-based amplification</article-title>. <source>Mol Biochem Parasitol</source>
<year>2004</year>;<volume>137</volume>:<fpage>35</fpage>–<lpage>41</lpage><pub-id pub-id-type="pmid">15279949</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousema</surname><given-names>T</given-names></name><name><surname>Okell</surname><given-names>L</given-names></name><name><surname>Shekalaghe</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs</article-title>. <source>Malar J</source>
<year>2010</year>;<volume>9</volume>:<fpage>136</fpage><pub-id pub-id-type="pmid">20497536</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okell</surname><given-names>LC</given-names></name><name><surname>Drakeley</surname><given-names>CJ</given-names></name><name><surname>Bousema</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity</article-title>. <source>PLoS Med</source>
<year>2008</year>;<volume>5</volume>:<fpage>e226</fpage>; <comment>discussion e26</comment><pub-id pub-id-type="pmid">19067479</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendez</surname><given-names>F</given-names></name><name><surname>Munoz</surname><given-names>A</given-names></name><name><surname>Plowe</surname><given-names>CV</given-names></name></person-group>
<article-title>Use of area under the curve to characterize transmission potential after antimalarial treatment</article-title>. <source>Am J Trop Med Hyg</source>
<year>2006</year>;<volume>75</volume>:<fpage>640</fpage>–<lpage>4</lpage><pub-id pub-id-type="pmid">17038686</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Seidlein</surname><given-names>L</given-names></name></person-group>
<article-title>Mini primaquine? Controversy and uncertainty surround WHO guidelines for the antimalarial primaquine</article-title>. <source>PLoS Blogs</source>
<year>2012</year></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laufer</surname><given-names>MK</given-names></name></person-group>
<article-title>Monitoring antimalarial drug efficacy: current challenges</article-title>. <source>Curr Infect Dis Rep</source>
<year>2009</year>;<volume>11</volume>:<fpage>59</fpage>–<lpage>65</lpage><pub-id pub-id-type="pmid">19094826</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="book"><collab>Organization WH</collab>
<source>Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>, <year>2007</year></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chomcharn</surname><given-names>Y</given-names></name><name><surname>Surathin</surname><given-names>K</given-names></name><name><surname>Bunnag</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Effect of a single dose of primaquine on a Thai strain of Plasmodium falciparum</article-title>. <source>Southeast Asian J Trop Med Public Health</source>
<year>1980</year>;<volume>11</volume>:<fpage>408</fpage>–<lpage>12</lpage><pub-id pub-id-type="pmid">7003735</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>A</given-names></name><name><surname>Kamei</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Gametocytocidal effect of primaquine in a chemotherapeutic malaria control trial in North Sumatra, Indonesia</article-title>. <source>Southeast Asian J Trop Med Public Health</source>
<year>1989</year>;<volume>20</volume>:<fpage>351</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">2699082</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boudin</surname><given-names>C</given-names></name><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Molez</surname><given-names>JF</given-names></name><etal></etal></person-group>
<article-title>High human malarial infectivity to laboratory-bred Anopheles gambiae in a village in Burkina Faso</article-title>. <source>Am J Trop Med Hyg</source>
<year>1993</year>;<volume>48</volume>:<fpage>700</fpage>–<lpage>6</lpage><pub-id pub-id-type="pmid">8517489</pub-id></mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talman</surname><given-names>AM</given-names></name><name><surname>Domarle</surname><given-names>O</given-names></name><name><surname>McKenzie</surname><given-names>FE</given-names></name><etal></etal></person-group>
<article-title>Gametocytogenesis: the puberty of Plasmodium falciparum</article-title>. <source>Malar J</source>
<year>2004</year>;<volume>3</volume>:<fpage>24</fpage><pub-id pub-id-type="pmid">15253774</pub-id></mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilian</surname><given-names>AH</given-names></name><name><surname>Metzger</surname><given-names>WG</given-names></name><name><surname>Mutschelknauss</surname><given-names>EJ</given-names></name><etal></etal></person-group>
<article-title>Reliability of malaria microscopy in epidemiological studies: results of quality control</article-title>. <source>Trop Med Int Health</source>
<year>2000</year>;<volume>5</volume>:<fpage>3</fpage>–<lpage>8</lpage><pub-id pub-id-type="pmid">10672199</pub-id></mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallett</surname><given-names>RL</given-names></name><name><surname>Dunyo</surname><given-names>S</given-names></name><name><surname>Ord</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Chloroquine/sulphadoxine-pyrimethamine for Gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparum</article-title>. <source>PLoS Clin Trials</source>
<year>2006</year>;<volume>1</volume>:<fpage>e15</fpage><pub-id pub-id-type="pmid">16871318</pub-id></mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Fofana</surname><given-names>BDA</given-names></name><name><surname>Sagara</surname><given-names>I</given-names></name><name><surname>Dao</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Impact of artemisinin-based combination therapy on malaria transmission in Mali. <italic>5th MIM Pan-African Malaria Conference</italic></article-title>; <publisher-loc>Nairobi, Kenya</publisher-loc>, <year>2009</year></mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunders</surname><given-names>AE</given-names></name></person-group>
<article-title>The effect of a single dose of pyrimethamine and primaquine in combination upon gametocytes and sporogony of Laverania falcipara (Plasmodium falciparum) in Liberia</article-title>. <source>Bull World Health Organ</source>
<year>1961</year>;<volume>24</volume>:<fpage>650</fpage>–<lpage>3</lpage><pub-id pub-id-type="pmid">13709766</pub-id></mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeffery</surname><given-names>GM</given-names></name><name><surname>Young</surname><given-names>MD</given-names></name><name><surname>Eyles</surname><given-names>DE</given-names></name></person-group>
<article-title>The treatment of Plasmodium falciparum infection with chloroquine, with a note on infectivity to mosquitoes of primaquine- and pyrimethamine-treated cases</article-title>. <source>Am J Hyg</source>
<year>1956</year>;<volume>64</volume>:<fpage>1</fpage>–<lpage>11</lpage><pub-id pub-id-type="pmid">13339773</pub-id></mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousema</surname><given-names>T</given-names></name><name><surname>Churcher</surname><given-names>TS</given-names></name><name><surname>Morlais</surname><given-names>I</given-names></name><etal></etal></person-group>
<article-title>Can field-based mosquito feeding assays be used for evaluating transmission-blocking interventions?</article-title>
<source>Trends Parasitol</source><year>2013</year>;<volume>29</volume>:<fpage>53</fpage>–<lpage>9</lpage><pub-id pub-id-type="pmid">23273727</pub-id></mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackerras</surname><given-names>MJ</given-names></name><name><surname>Ercole</surname><given-names>QN</given-names></name></person-group>
<article-title>Observations on the action of quinine, atebrin and plasmoquine on the gametocytes of Plasmodium falciparum</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<year>1949</year>;<volume>42</volume>:<fpage>455</fpage>–<lpage>63</lpage><pub-id pub-id-type="pmid">18118367</pub-id></mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rieckmann</surname><given-names>KH</given-names></name><name><surname>McNamara</surname><given-names>JV</given-names></name><name><surname>Frischer</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum</article-title>. <source>Bull World Health Organ</source>
<year>1968</year>;<volume>38</volume>:<fpage>625</fpage>–<lpage>32</lpage><pub-id pub-id-type="pmid">4876731</pub-id></mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousema</surname><given-names>T</given-names></name><name><surname>Dinglasan</surname><given-names>RR</given-names></name><name><surname>Morlais</surname><given-names>I</given-names></name><etal></etal></person-group>
<article-title>Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers</article-title>. <source>PLoS ONE</source>
<year>2012</year>;<volume>7</volume>:<fpage>e42821</fpage><pub-id pub-id-type="pmid">22936993</pub-id></mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eziefula</surname><given-names>AC</given-names></name><name><surname>Gosling</surname><given-names>R</given-names></name><name><surname>Hwang</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Rationale for short course primaquine in Africa to interrupt malaria transmission</article-title>. <source>Malar J</source>
<year>2012</year>;<volume>11</volume>:<fpage>360</fpage><pub-id pub-id-type="pmid">23130957</pub-id></mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graves</surname><given-names>PM</given-names></name><name><surname>Gelband</surname><given-names>H</given-names></name><name><surname>Garner</surname><given-names>P</given-names></name></person-group>
<article-title>Primaquine for reducing Plasmodium falciparum transmission</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2012</year>;<volume>9</volume>:<fpage>CD008152</fpage><pub-id pub-id-type="pmid">22972117</pub-id></mixed-citation></ref><ref id="R62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Slutsker</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>The threat of artemisinin-resistant malaria</article-title>. <source>New Eng J Med</source>
<year>2011</year>;<volume>365</volume>:<fpage>1073</fpage>–<lpage>5</lpage><pub-id pub-id-type="pmid">21992120</pub-id></mixed-citation></ref><ref id="R63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okell</surname><given-names>LC</given-names></name><name><surname>Bousema</surname><given-names>T</given-names></name><name><surname>Griffin</surname><given-names>JT</given-names></name><etal></etal></person-group>
<article-title>Factors determining the occurrence of submicroscopic malaria infections and their relevance for control</article-title>. <source>Nat Commun</source>
<year>2012</year>;<volume>3</volume>:<fpage>1237</fpage><pub-id pub-id-type="pmid">23212366</pub-id></mixed-citation></ref><ref id="R64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okell</surname><given-names>LC</given-names></name><name><surname>Griffin</surname><given-names>JT</given-names></name><name><surname>Kleinschmidt</surname><given-names>I</given-names></name><etal></etal></person-group>
<article-title>The potential contribution of mass treatment to the control of Plasmodium falciparum malaria</article-title>. <source>PLoS ONE</source>
<year>2011</year>;<volume>6</volume>:<fpage>e20179</fpage><pub-id pub-id-type="pmid">21629651</pub-id></mixed-citation></ref></ref-list></back></article>